Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency

GlobeNewswire May 23, 2016

Pulse Biosciences Announces Closing of Initial Public Offering

GlobeNewswire May 23, 2016

Alimera Sciences to Present at the UBS Global Healthcare Conference

GlobeNewswire May 17, 2016

Alimera Sciences' ILUVIEN® Data Presented at SFO 2016

GlobeNewswire May 11, 2016

Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO

PR Newswire May 6, 2016

Alimera Sciences Announces First Quarter 2016 Financial Results

GlobeNewswire May 4, 2016

Stonegate Capital Partners Initiates Coverage on Alimera Sciences

Accesswire April 27, 2016

Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016

GlobeNewswire April 26, 2016

Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results

GlobeNewswire March 2, 2016

Alimera Sciences to Present at 36th Annual Cowen Healthcare Conference

GlobeNewswire February 29, 2016

Alimera Sciences to Report Fourth Quarter 2015 Financial Results on March 2, 2016

GlobeNewswire February 18, 2016

Alimera Sciences Announces ILUVIEN® J Code J7313 Is Now Active

PR Newswire January 4, 2016

Alimera Sciences Signs Agreement To Distribute ILUVIEN® In The Middle East

PR Newswire December 15, 2015

Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN® Slows Diabetic Retinopathy Progression

PR Newswire November 16, 2015

Alimera Sciences To Speak At Ophthalmology Innovation Summit 2015

PR Newswire November 9, 2015

Alimera Sciences Reports Third Quarter 2015 Financial Results

PR Newswire November 5, 2015

Alimera Sciences announces late breaking presentation of new ILUVIEN® Analysis During Retina Subspecialty day at AAO annual meeting 2015

PR Newswire November 4, 2015

Alimera Sciences Strengthens Financial Position

PR Newswire November 3, 2015

Alimera Sciences To Release Third Quarter Fiscal Year 2015 Financial Results

PR Newswire October 29, 2015

Alimera Sciences Limited Announces Availability Of Review Paper On Real World Experience With ILUVIEN®

PR Newswire September 28, 2015